Dear Readers

It is our great pleasure to welcome you to *Drugs: Real World Outcomes*, the latest offering from Adis that targets research involving the use of real-world data. We all know that the gold standard in research is the randomized controlled clinical trial; however, we all also know that these trials by the nature of their design fail to inform clinicians on many fronts. While they provide vital confirmation of efficacy and safety, they exclude many relevant patient groups, such as the elderly, children and those with co-morbidities, and they are conducted in ideal settings, with an expectation of high adherence rates. Clinicians need to know how their patients will respond to a drug in real life---and the potential impact of factors such as race, age, sex, co-morbidities, performance status and other medications.

*Drugs: Real World Outcomes* aims to provide a vehicle for dissemination and a forum for discussion of information about how drugs perform in daily clinical practice. We will include both original research and definitive reviews on the use of real-world data to help you evaluate health outcomes and make informed healthcare decisions on drugs, devices and other interventions.

Adis has been publishing high quality journals for over 40 years, with experience in the areas of drug treatment, drug safety, pharmacokinetics, pharmacoeconomics and molecular diagnostics amongst others, and has a current portfolio of more than 30 journals. *Drugs* was first published in 1971 and has developed a reputation as the go-to source of information on drug treatment and drug evaluation. Over the years, the family of *Drugs* has grown to include *Drug Safety*, *Drugs & Aging*, *BioDrugs,Pediatric Drugs* and *Drugs in R&D*. With *Drugs: Real World Outcomes*, we now apply our knowledge and experience to bring you investigations on drug utilization, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.

The journal will be published online only and will be entirely open access. Now that the Adis portfolio of journals has been successfully integrated into the production systems and online platforms provided by Springer, as an Adis Open journal we can offer authorsEfficient article submission, peer review and tracking processesExpedited publication timelinesHigh visibility thanks to unrestricted online accessEasy discoverability and access for readers to their workCitation tracking and inclusion in bibliographic databases

Additional benefits of being a part of Springer include the availability of innovative online features for every article via SpringerLink.

We are excited about the contribution the journal will be able to make to clinical practice by providing meaningful information for critical decision making. We welcome pre-submission enquiries, and look forward to working with you on *Drugs: Real World Outcomes*.

Dene C. Peters and Anton van Rensburg, Editors
